Zenagamtide: Following the Name and the Formulation
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Zenagamtide, previously called amycretin, combines GLP-1 and amylin receptor activity within one molecule. Following both names helps keep the research record connected. A 2025 first-in-human randomized trial studied oral amycretin in 144 participants. The main questions concerned safety, tolerability, and how the body handled the compound. Gastrointestinal events were common, and body-weight changes were explored. Early findings can support further trials without establishing a complete long-term benefit and risk profile. Oral and injectable formulations have separate study histories. Neither a shared name nor promising early results makes their effects interchangeable or establishes equivalence to a product outside the clinical program.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Amycretin investigators (2025): First-in-human phase 1 trial of oral amycretin
https://pubmed.ncbi.nlm.nih.gov/40550229/
Primary human randomized phase 1 trial

[2] Novo Nordisk (2026): Cardiometabolic pipeline update for EASD 2026
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916767
Official sponsor nomenclature and development update

EVIDENCE LIMITATIONS
The 2025 oral phase 1 study is historical evidence, not a statement that current development remains phase 1.
Exploratory weight change is not a definitive long-term efficacy result.
Oral and subcutaneous trial data must not be pooled or treated as interchangeable without justification.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Zenagamtide: Following the Name and the Formulation